Pharma Deals Review, Vol 2010, No 4 (2010)

Font Size:  Small  Medium  Large

Mersana and Teva in USD 334 M deal for preclinical cancer drug

Debbie Tranter

Abstract


Teva Pharmaceutical Industries has entered into an agreement with Mersana Therapeutics for rights to develop and commercialize XMT-1107 for the treatment of all indications, including cancer



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.